The NGS-based test, which was approved by the FDA in June, will be now available to the insurers' members, who have non-small cell lung cancer, in four states.
The developers hope that the NSCLC detection system they are developing could eventually be expanded to include biomarkers for other cancer types and diseases.
Recent work by researchers from Harvard and Moffitt Cancer Center demonstrated the potential usefulness of radiomics in combination with gene expression data.
